Baroletti Steven, Catella Jennifer, Ehle Michael, Cheng Judy W M
Department of Pharmacy, MetroWest Medical Center, Framingham, Massachusetts 01760, USA.
Crit Pathw Cardiol. 2010 Jun;9(2):94-101. doi: 10.1097/HPC.0b013e3181dda1e6.
Atrial fibrillation (AF) is a common arrhythmia associated with increased cardiovascular mortality, stroke, and hospitalization in the United States. Amiodarone is generally considered as the agent with the best efficacy for maintaining normal sinus rhythm. Despite its efficacy, amiodarone use is often limited by its extensive side effect profile. Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been recently approved by the Food and Drug Administration to reduce cardiovascular hospitalization in patients with AF or atrial flutter. Structural modification of dronedarone was introduced to shorten the half-life, decrease lipophilicity, and minimize noncardiovascular toxicity as compared to amiodarone. This article reviews the pharmacology, adverse effects, and clinical evidence available to date of the use of dronedarone in the management of AF.
心房颤动（AF）是一种常见的心律失常，在美国与心血管疾病死亡率增加、中风和住院率升高相关。胺碘酮通常被认为是维持正常窦性心律疗效最佳的药物。尽管其疗效显著，但胺碘酮的使用常常因其广泛的副作用而受到限制。决奈达隆是胺碘酮的一种非碘化苯并呋喃衍生物，最近已获美国食品药品监督管理局批准，用于减少心房颤动或心房扑动患者的心血管住院率。与胺碘酮相比，决奈达隆进行了结构修饰，以缩短半衰期、降低亲脂性并将非心血管毒性降至最低。本文综述了决奈达隆用于心房颤动治疗的药理学、不良反应及目前可用的临床证据。
